Inflammatory pathways to liver fibrosis in non-alcoholic and alcoholic steatohepatitis: reversal by NLRP3 inhibitors

非酒精性和酒精性脂肪性肝炎中肝纤维化的炎症途径：NLRP3抑制剂逆转

• 批准号: nhmrc : 1129208
• 负责人: A/Pr Kate Schroder
• 金额: $ 39.08万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/inflammatory-pathways-liver-nlrp3-inhibitors/948367
• 关键词: Inflammatory; pathways; liver; fibrosis; non

Nonalcoholic steatohepatitis (NASH) caused by obesity and diabetes made worse by alcohol, leads to cirrhosis. There is no effective treatment. In mice with NASH, MCC950, a novel drug that blocks NLRP3 (molecule that incites inflammation) reverses liver inflammation and possibly scarring. This proposal will test what activates NLRP3 in NASH, and whether blocking it completely with MCC950 or a new lasting longer inhibitor will dissolve severe liver scarring, and scarring made worse by alcohol.

由肥胖和糖尿病引起的非酒精性脂肪性肝炎（NASH）因酒精而加重，可导致肝硬化。没有有效的治疗方法。在患有NASH的小鼠中，一种阻断NLRP3（刺激炎症的分子）的新药MCC950可以逆转肝脏炎症和可能的瘢痕形成。这项提议将测试是什么激活了NASH中的NLRP3，以及用MCC950或一种新的持续时间更长的抑制剂完全阻断NLRP3是否会溶解严重的肝脏疤痕，以及酒精导致的更严重的疤痕。